Dr. Adam STOTEN, Deputy Head of Technology Transfer at ISIS Innovation Ltd, the technology transfer company of the University of Oxford will be sharing his experiences in the following panel:
“Scouting innovation: academia push and industry pull” on december 3rd and 4pm
Academia wants to push out knowledge and innovation on the one hand and the industry is looking to pull it in and bring it to market on the other hand. However simple this might seem, when putting it into practice there are many challenges to overcome. Let’s find out which are the new models that pharma and biotech are using in scouting the innovation and how are TTOs better packaging the offer in order to find more matches with the demand?
Dr. Adam STOTEN’s biography
Adam joined Isis in the role of Deputy Head of Technology Transfer in 2013, with specific responsibility for commercialisation of life/medical science technologies originating from Oxford research. Adam has worked for more than a decade in the pharma/biotech sector in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management. Between 2010 and 2013 Adam worked for Emergent BioSolutions Inc as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture with the University of Oxford which conducted the first ever efficacy study of a new TB vaccine in infants. Adam first worked at Isis between 2005 and 2010, successfully managing a wide range of licensing deals and spin-outs spanning therapeutics, vaccines, diagnostics, research tools and software. Prior to 2005 he worked as Head of Research for a specialist pharma/biotech consultancy undertaking due diligence and market research projects. Adam has a 1st Class Honours degree in biology and a PhD in immunology from the University of Nottingham.
